TY - JOUR
T1 - Noninvasive measurements of infarct size after thrombolysis with a necrosis-avid MRI contrast agent
AU - Pislaru, Sorin V.
AU - Ni, Yicheng
AU - Pislaru, Cristina
AU - Bosmans, Hilde
AU - Miao, Yi
AU - Bogaert, Jan
AU - Dymarkowski, Steven
AU - Semmler, Wolfhard
AU - Marchal, Guy
AU - Van De Werf, Frans J.
PY - 1999/2/9
Y1 - 1999/2/9
N2 - Background-Gadophrin-2 is a new MRI contrast agent with high affinity for necrotic myocardium. The aim of the study was to evaluate whether noninvasive measurements of infarct size after thrombolysis are possible with gadophrin-2-enhanced MRI. Methods and Results-Coronary artery thrombosis was induced in 3 groups of dogs by the copper-coil technique. Thrombolytic therapy together with aspirin and heparin was initiated after 90 minutes of occlusion. One day (group A), 2 days (group B), or 6 days (group C) after infarction, gadophrin-2 was injected intravenously (50 μmol · kg-1). In vivo T1-weighted segmented turbo-FLASH, in vivo T2-weighted segmented half- Fourier turbo spin echo (HASTE), and T1 and T2-weighted spin-echo MRI of the excised heart were performed 24 hours after gadophrin-2 injection. Regions of strong enhancement were observed on T1-weighted images. Planimetry of short- axis MR images and of corresponding triphenyltetrazolium chloride (TTC)- stained left ventricular (LV) slices showed a close correlation between the enhanced areas and TTC-negative areas for both in vivo (r2=0.98, P < 0.0001; mean difference, 0.9 ± 2.0% [SD] of the LV volume [LVV]) and postmortem (r2 = 0.99, P < 0.0001; mean difference, 0.9 ± 1.4% of LVV) measurements. T2- weighted images overestimated the infarct size by 8.1 ± 5.4% of LVV. The mean infarct size was 10.8 ± 11.6% of LVV (group A), 22.4 ± 11.7% (group B), and 5.1 ± 9.3% (group C). Conclusions-In this animal model, in vivo gadophrin-2-enhanced MRI could precisely determine infarct size after thrombolytic therapy. This technique may be very useful for the noninvasive evaluation of infarct size after reperfusion for AMI.
AB - Background-Gadophrin-2 is a new MRI contrast agent with high affinity for necrotic myocardium. The aim of the study was to evaluate whether noninvasive measurements of infarct size after thrombolysis are possible with gadophrin-2-enhanced MRI. Methods and Results-Coronary artery thrombosis was induced in 3 groups of dogs by the copper-coil technique. Thrombolytic therapy together with aspirin and heparin was initiated after 90 minutes of occlusion. One day (group A), 2 days (group B), or 6 days (group C) after infarction, gadophrin-2 was injected intravenously (50 μmol · kg-1). In vivo T1-weighted segmented turbo-FLASH, in vivo T2-weighted segmented half- Fourier turbo spin echo (HASTE), and T1 and T2-weighted spin-echo MRI of the excised heart were performed 24 hours after gadophrin-2 injection. Regions of strong enhancement were observed on T1-weighted images. Planimetry of short- axis MR images and of corresponding triphenyltetrazolium chloride (TTC)- stained left ventricular (LV) slices showed a close correlation between the enhanced areas and TTC-negative areas for both in vivo (r2=0.98, P < 0.0001; mean difference, 0.9 ± 2.0% [SD] of the LV volume [LVV]) and postmortem (r2 = 0.99, P < 0.0001; mean difference, 0.9 ± 1.4% of LVV) measurements. T2- weighted images overestimated the infarct size by 8.1 ± 5.4% of LVV. The mean infarct size was 10.8 ± 11.6% of LVV (group A), 22.4 ± 11.7% (group B), and 5.1 ± 9.3% (group C). Conclusions-In this animal model, in vivo gadophrin-2-enhanced MRI could precisely determine infarct size after thrombolytic therapy. This technique may be very useful for the noninvasive evaluation of infarct size after reperfusion for AMI.
KW - Diagnosis
KW - Magnetic resonance imaging
KW - Myocardial infarction
KW - Thrombolysis
UR - http://www.scopus.com/inward/record.url?scp=0033537504&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033537504&partnerID=8YFLogxK
U2 - 10.1161/01.CIR.99.5.690
DO - 10.1161/01.CIR.99.5.690
M3 - Article
C2 - 9950668
AN - SCOPUS:0033537504
SN - 0009-7322
VL - 99
SP - 690
EP - 696
JO - Circulation
JF - Circulation
IS - 5
ER -